ImmunoGen Announces Webcast of Presentation and QA at Upcoming Canaccord Genuity 43rd Annual Growth Conference
About 67% of ImmunoGen's investor base is looking to short. The analysis of current outlook of investing in ImmunoGen suggests that many traders are alarmed regarding ImmunoGen's prospects. ImmunoGen's investing sentiment overview a quick insight into current market opportunities from investing in ImmunoGen. Many technical investors use ImmunoGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ImmunoGen |
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that t
Read at businesswire.com
 |
ImmunoGen Fundamental Analysis
We analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
ImmunoGen is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
ImmunoGen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoGen stock to make a market-neutral strategy. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics with similar companies.
Peers
ImmunoGen Related Equities
| XFOR | X4 Pharmaceuticals | 8.11 | ||||
| TGTX | TG Therapeutics | 5.47 | ||||
| MCRB | Seres Therapeutics | 4.11 | ||||
| AKRO | Akero Therapeutics | 2.87 | ||||
| HOOK | Hookipa Pharma | 2.00 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.65 | ||||
| AXSM | Axsome Therapeutics | 0.89 | ||||
| VKTX | Viking Therapeutics | 0.70 | ||||
| INZY | Inozyme Pharma | 0.83 | ||||
| TERN | Terns Pharmaceuticals | 1.86 | ||||
| MREO | Mereo BioPharma | 2.04 | ||||
| PDSB | PDS Biotechnology | 2.21 | ||||
| ELEV | Elevation Oncology | 5.45 | ||||
| HEPA | Hepion Pharmaceuticals | 7.14 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |